Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | CSF1R | P07333 | 14/20 | 0.52 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15208619 | 0.92 | KDM4E (0.51) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723994 | 0.89 | CSF1R (0.59) | CSF1RCYP3A4CYP2C9 | |
| SCHEMBL2723463 | 0.86 | CSF1R (0.57) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2726227 | 0.85 | CSF1R (0.58) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2726945 | 0.84 | CSF1R (0.57) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723598 | 0.84 | CYP3A4 (0.52) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723613 | 0.83 | CSF1R (0.63) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723683 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723375 | 0.83 | KDM4E (0.59) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R | |
| SCHEMBL2723941 | 0.83 | MTOR (0.60) | KDM4EALDH1A1SMN1; SMN2RXFP1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2635279-A2 | CHEMICAL COMPOUNDS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-11 | — | — | EP | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| WO-2012061557-A2 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | KDM4E 1541/4885ALDH1A1 33/4885SMN1; SMN2 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.